Phenylbutazone (Bute, PBZ, EPZ): one drug across two species
Tóm tắt
Từ khóa
Tài liệu tham khảo
Abraham, J. (1995). Science, politics and the pharmaceutical industry: Controversy and bias in drug regulation. London: UCL Press.
Ackerknecht, E. H. (1974). Therapeutics: From primitives to the twentieth century. New York: Hafer Press.
Anon. (1979). Pharmacology review: The non-steroidal anti-inflammatory drugs. I. Phenylbutazone. Journal of Equine Medicine and Surgery, 3, 253–258.
Anon (1980). Duke opposes ban on the use of painkiller on horses. Times, 5 Sept, 3.
Aronson, J. K. (2009). Meyler’s side effects of analgesics and anti-inflammatory drugs. Amsterdam: Elsevier.
Atkinson, J. (1900). “Doping” racehorses. Daily News, 14 November, 8.
Benedek, T. G. (2011). History of the development of corticosteroid therapy. Clinical and Experimental Rheumatology, 29(Suppl. 68), S5–S12.
Bogan, J. A. (1972). The determination of phenylbutazone in horse plasma. Veterinary Record, 90(7), 199.
Bonnie, E. S. (1982). Corrupt Horse Racing Practices Act of 1980: A threat to state control of horse racing. Kentucky Law Journal, 70, 1159–1179.
Brooks, P. M., & Buchanan, W. W. (1985). The introduction of new non-steroidal anti-inflammatory drugs. In N. M. Hadler & D. B. Gillings (Eds.), Arthritis and society: The impact of musculoskeletal diseases (pp. 206–229). London: Butterworths.
Brown, S. (1983). Is this what the doctor ordered? TVTimes Magazine, 23–29 April, 63.
Bud, R. (2007). Penicillin: Triumph and tragedy. Oxford: Oxford University Press.
Burns, J. J. (1968). Variation of drug metabolism in animals and the prediction of drug action in man. Annals of the New York Academy of Sciences, 151(1), 959–967.
Burns, J. J., et al. (1953). The physiological disposition of phenylbutazone (Butazolidin) in man and a method for its estimation in biological material. Journal of Pharmacology and Experimental Therapy, 109(3), 346–357.
Burns, J. J., et al. (1960). Biochemical pharmacological considerations of phenylbutazone and its analogues. Annals of the New York Academy of Sciences, 86(1), 253–262.
Cantor, D. (1991). The aches of industry: Philanthropy and rheumatism in inter-war Britain. In J. Barry & C. Jones (Eds.), Medicine and charity before the welfare state (pp. 225–245). London and New York: Routledge.
Cantor, D. (1992). Cortisone and the politics of drama, 1949–1955. In J. V. Pickstone (Ed.), Medical innovations in historical perspective (pp. 165–184). New York: St. Martin’s Press.
Carlisle, C. H., et al. (1968). Toxic effects of phenylbutazone on the cat. British Veterinary Journal, 124, 560–567.
Carpenter, S. L., & McDonnell, W. M. (1995). Misuse of veterinary phenylbutazone. Archives of Internal Medicine, 155, 1229–1231.
Cassidy, R. (2002). The sport of kings: Kinship, class and thoroughbred breeding in Newmarket. Cambridge: Cambridge University Press.
Committee. (1978). Committee on the review of medicines. British Medical Journal, 1(6126), 1466–1467.
Copeman, W. S. C. (1964). A short history of the gout and the rheumatic diseases. Berkeley: University of California Press.
Copeman, W. S. C., & Mason, R. M. (1954). Rheumatism, fibrositis, arthritis, lumbago, sciatica, “Slipped Disc”, gout, spondylitis. London: Duckworth.
Current Concepts in Therapy. (1957). Analgesic drugs. VI. Non-narcotics. V. Pyrazolon derivatives. New England Journal of Medicine, 275, 716.
Dalton, P. J. (1956). The use of phenylbutazone to control pain in veterinary practice. British Veterinary Journal, 12, 128–130.
Dudley Hart, F., & Boardman, P. L. (1963). Indomethacin: A new non-steroidal anti–inflammatory agent. British Medical Journal, 2(5363), 965–970.
Dudley Hart, F., & Johnson, A. M. (1952). Treatment of rheumatoid arthritis with Butazolidine. Lancet, 2(6723), 43.
Dunn, P. S. (1972). A clinician’s views on the use and misuse of phenylbutazone. Equine Veterinary Journal, 4(2), 63–65.
Duthie, J. J. (1964). Rheumatoid arthritis. In W. S. C. Copeman (Ed.), Textbook of the rheumatic diseases (3rd ed., pp. 175–239). Edinburgh: E. & S. Livingstone.
Duthie, J. J. (1970). Rheumatoid arthritis. In W. S. C. Copeman (Ed.), Textbook of the rheumatic diseases (4th ed., pp. 259–322). Edinburgh: E. & S. Livingstone.
Editorial. (1981). Science and the administration of phenylbutazone. Equine Veterinary Journal, 13(3), 144–145.
Editorial. (2013). Shutting the door after the horse (on phenylbutazone) has bolted. Veterinary Journal, 196, 273.
Faich, G. A. (1987). Risk and indications of phenylbutazone: another look. Pharmacotherapy, 7, 25–27.
Forestier, J. (1934). Rheumatoid arthritis and its treatment by gold salts. Lancet, 2(5795), 646–648.
Gabel, A. A., et al. (1977). Phenylbutazone in horses: A review. Journal of Equine Medicine and Surgery, 1, 221–225.
Green, L. (1995). The black mark over “Bute”. Daily Telegraph, 4 September, 58.
Hetenyi, G., Jr., & Karsh, J. (1997). Cortisone therapy: A challenge to academic medicine in 1949–1952. Perspectives on Biology and Medicine, 40(3), 426–439.
Higgins, F. A. (2006). From ancient Greece to modern Athens: 3000 years of doping in competition horses. Journal of Veterinary Pharmacology and Therapeutics, 29, 4–8.
Higgins, A. J., & Snyder, J. R. (2006). The equine manual (2nd ed.). Edinburgh: Elsevier Saunders.
Hopes, R. (1972). Uses and misuses of anti-inflammatory drugs in racehorses: I. Equine Veterinary Journal, 4(2), 66–68.
H.R. 7254 (1980). U.S. House of representatives—Corrupt Horseracing Practices Act of 1980.
Hunt, T. M., et al. (2014). Drugs, the law, and the downfall of Dancer’s Image at the 1968 Kentucky Derby: A case study on human conceptions of domesticated animals. International Journal of the History of Sport, 31(8), 902–913.
Inman, W. H. W. (1977). Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. British Medical Journal, 1(6075), 1500–1505.
Jeffcott, L. B., & Colles, C. M. (1977). Phenylbutazone and the horse. Equine Veterinary Journal, 9(3), 105–110.
Jones, Susan D. (2003). Valuing animals: Veterinarians and their patients in modern America. Baltimore: Johns Hopkins University Press.
Korziol, R., & Milbert, N. (1979). Drugs, legal and illegal, traumatize horse racing, Chicago Tribune, 6 May, Section 4, 1 and 6.
Laurence, W. L. (1952). New drug hailed as arthritis aid. New York Times, 7 June, 17.
Laurence, W. L. (1953). New drug combats crippling diseases. New York Times, 30 May, 30.
Lawrence, J. (1971). Matters of some substance. Daily Telegraph, 29 August, 25.
Lees, P., & Higgins, A. J. (1985). Clinical pharmacology and therapeutic uses of non-steroidal anti- inflammatory drugs in the horse. Equine Veterinary Journal, 17, 83–96.
Lees, P., & Toutain, P.-L. (2013). Properties relevant to safety of humans consuming horse meat containing phenylbutazone and its metabolites. Equine Veterinary Education, 25(11), 545–549.
Lees, P., et al. (1983a). Biochemical and haematological effects of phenylbutazone in horses. Equine Veterinary Journal, 15(2), 158–167.
Lees, P., et al. (1983b). Biochemical and haematological effects of phenylbutazone in horses. Equine Veterinary Journal, 15, 158–167.
Lees, P., et al. (2004). Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest. Journal of Veterinary Pharmacology and Therapeutics, 27, 479–490.
Leonard, J. C. (1953). Toxic effects of phenylbutazone with special reference to disorders of the blood. British Medical Journal, 1(4823), 1311.
Longrigg, R. (1972). The history of horse racing. London: Macmillan.
MacAllister, C. G. (1983). Effects of toxic doses of phenylbutazone in ponies. American Journal of Veterinary Research, 44(12), 2277–2279.
Macgregor-Morris, P. (1976). Drug ban in dressage may be the thin end of the wedge. Times, 9 December, 13.
Macgregor-Morris, P. (1980a). Dope has no place in top people’s prize ring, Times, 30 October, 11.
Macgregor-Morris, P. (1980b). Drugs are top of the federation agenda, Times, 9 December, 9.
MacTavish, J. R. (2004). The industrial history of analgesics: The evolution of analgesics and antipyretics. In K. D. Rainsford (Ed.), Aspirin and related drugs (pp. 25–43). London: Taylor and Francis.
Marks, H. (1991). Cortisone, 1949: A year in the political life of a drug. Bulletin of the History of Medicine, 66(3), 419–439.
McArthur, J. (2009). Badminton director joins row over new drug rules. Times, 1 December, 70.
McCarthy, D. D., & Chalmers, T. M. (1964). Hematological complications of phenylbutazone therapy: Review of the literature and report of two cases. Canadian Medical Association Journal, 90, 1061–1067.
Miller, W. C., & Moss, M. S. (1964). The analyst versus the horse-dope. New Scientist, pp. 737–738.
Mintz, M. (1986). Drug company settles in skin-loss case. Washington Post, 6 November.
Mold, A. (2015). Making the patient-consumer: Patient organisations and health consumerism in Britain. Manchester: Manchester University Press.
Moss, M. S. (1972). Uses and misuses of anti-inflammatory drugs in racehorses—II. Equine Veterinary Journal, 4(2), 69–73.
Moss, M. S., & Haywood, P. E. (1973). Persistence of phenylbutazone in horses producing acid urines. Veterinary Record, 93(5), 124–125.
O’Brien, J., & Herbert, I. (2005). Vincent O’Brien: The official biography. London: Bantam Press.
Paul, B. (1984). Risks versus benefits: How a drug company deals with disputs over its medicine. Wall Street Journal, 1 June, 1.
Phenylbutazone. (1965). Phenylbutazone. British Medical Journal, 2(5465), 773–774.
Pieters, T., & Snelders, S. (2005). Mental ills and the “hidden history” of drug treatment practices. In M. Gijswijt-Hofstra et al. (Eds.), Psychiatric cultures compared: Psychiatry and mental health care in the twentieth century: Comparisons and approaches (pp. 381–401). Amsterdam: Amsterdam University Press.
Podolsky, S. H. (2015). The antibiotic era: Reform, resistance, and the pursuit of a rational therapeutics. Baltimore: Johns Hopkins University Press.
Poulter, S., & Rush, J. (2013). Drug-tainted horse meat may have entered the food chain. Daily Mail, 23 February.
Prior-Palmer, L. (1976). Why Wide Awake died. Daily Telegraph, 11 September, 56–57.
Report. (1900). What is “doping”? A meeting of inquiry: An inconclusive result. Daily News, 20 November, 7.
Report. (1953). Hazards of phenylbutazone treatment. Lancet, 1(6773), 1236–1237.
Report. (1985). Sale of Tanderil discontinued by Ciba-Geigy. Lancet, 1(8433), 882.
Report. (2010). FEI plan for bute in equestrian competition turns full circle. Horse & Hound, 17 September.
Rodnan, G. P., & Benedek, T. G. (1970). The early history of anti-rheumatic drugs. Arthritis and Rheumatism, 13, 145–165.
Rollin, B. E. (2006). An introduction to veterinary medical ethics: Theory and cases. London: Wiley Blackwell.
Rossdale, P., Jackson, P., & Cox, T. (Eds.). (2011). The history of equine veterinary practice in Newmarket from 1831 to 2011. Newmarket: Romney Publications.
Royal Society of Medicine. (1953). Phenylbutazone. Lancet, 1(6773), 1231–1232.
S. 2636 (1980). U. S. Senate—Corrupt Horseracing Practices Act of 1980.
Sarett, L. (1990). An interview conducted by Leon Gortler. 6 September. Chemical Heritage Foundation.
Schiebla, S. H. (1984). Drug on the market: Examining what’s wrong with the FDA. Barron’s 16 April, 22.
Schlünder, M., & Schlich, T. (2009). The emergence of “Implant-pets” and “Bone-sheep”. Animals as new biomedical objects. History and Philosophy of Life Sciences, 31, 433–466.
Science Media Centre (2013). Expert reaction to the continuing horsemeat story and bute (phenylbutazone). http://www.sciencemediacentre.org/expert-reaction-to-the-continuing-horsemeat-story-and-bute-phenylbutazone/ . Accessed 17 Oct 2013.
Shen, T. Y., et al. (1963). Non-steroidal anti-inflammatory agents. Journal of the American Chemical Society, 85, 488–489.
Shenton, J., & Adams, J. (Eds.). (1983). Kill or cure? Drug injury and what to do about it. London: Channel 4 Television.
Silverman, M., Lydecker, M., & Lee, P. (1992). Bad medicine: The prescription drug industry in the third world. Redwood City: Stanford University Press.
Smith, A. (1980). Delegates vote in favour of “bute”. Daily Telegraph, 12 December, 27.
Smith, A. (1989). Federation vote to reduce “bute” level. Daily Telegraph, 24 March, 26.
Snow, D. H., et al. (1981). Phenylbutazone toxicosis in equidae: A biochemical and pathophysiological study. American Journal of Veterinary Research, 42(10), 1754–1759.
Soma, L. R. (2012). The use of phenylbutazone in the horse. Journal of Veterinary Pharmacology and Therapeutics, 35, 1–12.
Sperling, I. L. (1969). Adverse reactions with long-term use of phenylbutazone and oxyphenbutazone. Lancet, 2(7619), 535.
Struthers, G., et al. (1984). The rattled CSM should think again. British Journal of Medicine, 289(6440), 318.
Symposium (1953a). Butazolidin symposium: Clinical and experimental observations. British Medical Journal, 2(4847), 1213–1214.
Symposium (1953b). Phenylbutazone: Empire Rheumatism Council’s discussion. Lancet, 2(6796), 1145–1147.
Tandy, J., & Thorpe, E. (1967). A fatal syndrome in a dog following administration of phenylbutazone. Veterinary Record, 81(16), 398–399.
Tobin, T. (1981). Drugs and the performance horse. Springfield: Charles C. Thomas.
Tobin, T., et al. (1986). Phenylbutazone in the horse: A review. Journal of Veterinary Pharmacology and Therapeutics, 9, 1–12.
Toby, M. C. (2011). Dancer’s image: The forgotten story of the 1968 Kentucky Derby. New York: The History Press.
Tomes, N. (2016). Remaking the American patient: How Madison Avenue and modern medicine turned patients into consumers. Chapel Hill, NC: University of North Carolina Press.
Vamplew, W. (1976). The turf: A social and economic history of horse racing. London: Allen Lane.
Veitch, A. (1983). Group of drugs likely to be banned. Guardian. 30 December, 1.
von Rechenberg, H. K. (1957). Phenylbutazon: Butazolidin. Unter besonder berücksichtgung de nebenwirkungen. Stuttgart: Georg Thieme.
von Rechenberg, H. K. (1961). Butazolidin Phenylbutazon (2nd ed.). Stuttgart: Georg Thieme.
von Rechenberg, H. K. (1962). Phenylbutazone: Butazolodin. London: Edward Arnold.